CYPHERPUNK TECHNOLOGIES INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 24 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-16 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-26 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-24 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-12 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-16 | |
| 2017-12-31 | $0.00 10-K · filed 2019-04-01 | $0.00 10-K · filed 2018-02-23 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |